This HTML5 document contains 125 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q53617381
rdf:type
wikibase:Item
schema:description
مقالهٔ علمی wetenschappelijk artikel บทความทางวิทยาศาสตร์ teaduslik artikkel научная статья vědecký článek 2006年學術文章 naučni članak vetenskaplig artikel artykuł naukowy artikull shkencor სამეცნიერო სტატია мақолаи илмӣ artículu científicu tieteellinen artikkeli vitskapeleg artikkel artigo científico (publicado na 2006) scienca artikolo vedecký článok мақолаи илмӣ 2006 nî lūn-bûn tudományos cikk artigo científico 2006年学术文章 научна статия 2006年学术文章 article scientific videnskabelig artikel (udgivet 2006) wissenschaftlicher Artikel 2006年學術文章 научни чланак article scientifique (publié 2006) articol științific سائنسی مضمون 2006年學術文章 2006年学术文章 vitenskapelig artikkel mokslinis straipsnis article científic 2006년 논문 2006年学术文章 наукова стаття, опублікована в червні 2006 scientific article bài báo khoa học מאמר מדעי 2006年學術文章 artikulong pang-agham مقالة علمية ২০০৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artigo científico (publicado na 2006) научни чланак bilimsel makale 2006年學術文章 գիտական հոդված 2006年学术文章 2006年の論文 2006年學術文章 articolo scientifico επιστημονικό άρθρο artículo científico publicado en 2006
p:P577
wds:Q53617381-75FC220E-BFC7-4B1A-B868-2559B8D33A1D
wdt:P577
2006-06-15T00:00:00Z
p:P407
wds:Q53617381-CFDF239B-5619-4A23-953B-0C8CB8D7CA2D
wdt:P407
wd:Q1860
p:P2860
wds:Q53617381-E3FF78B7-ED40-496F-94CC-794F6ECC7AE1 wds:Q53617381-E9676B64-0CDA-4B9D-959D-0800C2D46868 wds:Q53617381-C79CFD82-10FC-420D-85E6-3D4646368300 wds:Q53617381-DA7B6241-ED28-4546-95E4-DF81A690BE96 wds:Q53617381-D84B32DF-1EF4-4131-A3C5-46B8B0DEEAAD wds:Q53617381-51838F9E-065D-4C89-A991-3D6AE89B8350 wds:Q53617381-5D722EBB-FC73-47D6-A889-0903EFBCEBAF wds:Q53617381-789962CC-EE10-4B3A-98CC-C3B797440858 wds:Q53617381-06CA00B6-4E8C-4D2F-8B81-410627688D61 wds:Q53617381-1529E2F1-2C49-434A-805E-2540ECB04CBF wds:Q53617381-1C25C733-77AA-4132-AA15-1B9CB1602FB5 wds:Q53617381-428D7952-442F-4F95-8A31-6F2A0B8F38A7 wds:Q53617381-3D8E4159-C2AB-4CA0-A7D1-B954FF7FAEBD
wdt:P2860
wd:Q35974612 wd:Q33346522 wd:Q59647356 wd:Q54041945 wd:Q29615133 wd:Q57618520 wd:Q54061091 wd:Q33334292 wd:Q45057186 wd:Q33339347 wd:Q35226263 wd:Q33500327 wd:Q33357108
p:P2093
wds:Q53617381-E11846F8-1135-4E5E-9A79-BDDF7BD605E6 wds:Q53617381-1AAABEEE-7F7A-4BF6-9FC3-AC772146F85E wds:Q53617381-B8B340B8-D745-48ED-8425-D99CB2F045E2 wds:Q53617381-95439247-7AAE-40A8-934A-B49F4EDBBE6E wds:Q53617381-56662A83-8C36-4A0D-861B-B9FDBF610E61
wdt:P2093
Janet S Rader Randall Gibb Thomas J Herzog David G Mutch Matthew A Powell
rdfs:label
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
skos:prefLabel
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
schema:name
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
p:P1476
wds:Q53617381-52AAF6BB-918F-43B8-AE7A-463B601C96C4
wdt:P1476
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
p:P304
wds:Q53617381-EAC5E3C8-1597-482A-8581-C513A56D055A
wdt:P304
637-641
p:P31
wds:Q53617381-09F22BC1-83E1-4A39-9D75-0CB4B97E06C2
wdt:P31
wd:Q13442814
p:P698
wds:Q53617381-9EEB381C-8793-4028-9858-B326CCA8F73A
wdtn:P698
n12:16781766
wdt:P698
16781766
p:P1433
wds:Q53617381-91F02959-EAF9-4EBE-99F1-EC59B814220D
wdt:P1433
wd:Q5625182
p:P433
wds:Q53617381-5A5BB928-A346-4D2D-AD05-8384F5388770
p:P478
wds:Q53617381-3678A67F-ED2D-4194-B115-89F1782CDD25
wdt:P433
2
wdt:P478
103
p:P356
wds:Q53617381-7B2A6859-B9A0-4485-8AD3-CBF0F855D420
wdtn:P356
n11:J.YGYNO.2006.04.014
wdt:P356
10.1016/J.YGYNO.2006.04.014